Genmab A/S
NASDAQ:GMAB
Wall Street
Price Targets
GMAB Price Targets Summary
Genmab A/S
According to Wall Street analysts, the average 1-year price target for
GMAB
is 123.74 USD
with a low forecast of 27.12 USD and a high forecast of 459.16 USD.
GMAB Last Price Targets
Genmab A/S
The latest public price target was made on Feb 6, 2023 by
Unknown Analyst
from
Leerink Partners
,
who expects
GMAB
stock to
rise by 26%
over the next 12 months.
You can read more about this price target by viewing
the article on Benzinga.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Unknown Analyst
Leerink Partners
|
36
USD
Upside 26% |
1 year ago
Feb 6, 2023
|
SVB Leerink Maintains Market Perform on Genmab, Raises Price Target to $36
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is GMAB's stock price target?
Price Target
123.74
USD
According to Wall Street analysts, the average 1-year price target for
GMAB
is 123.74 USD
with a low forecast of 27.12 USD and a high forecast of 459.16 USD.
What is Genmab A/S's Revenue forecast?
Projected CAGR
19%
For the last 8 years the
compound annual growth rate for
Genmab A/S's revenue is
40%.
The projected
CAGR
for the next 3 years is
19%.
What is Genmab A/S's Operating Income forecast?
Projected CAGR
25%
For the last 8 years the
compound annual growth rate for
Genmab A/S's operating income is
28%.
The projected
CAGR
for the next 3 years is
25%.
What is Genmab A/S's Net Income forecast?
Projected CAGR
27%
For the last 8 years the
compound annual growth rate for
Genmab A/S's net income is
24%.
The projected
CAGR
for the next 3 years is
27%.
You don't have any saved screeners yet
